Each year over half a million people experience permanent hearing loss caused by
treatment with therapeutic drugs with ototoxic side effects. There is a major unmet clinical …

The purpose of this report is to provide guidance on the use of otoacoustic emissions (OAEs)
as a clinical trial outcome measure for pharmaceutical interventions developed to prevent …

Objectives: Distortion-product otoacoustic emissions (DPOAEs) are repeatable over time at
lower frequencies (≤ 8 kHz) and higher frequencies (> 8 kHz) in healthy, normal-hearing …

Objectives: Serological biomarkers, common to many areas of medicine, have the potential
to inform on the health of the human body and to give early warning of risk of compromised …

Purpose: Distortion product otoacoustic emissions (DPOAEs) provide an objective
assessment of cochlear function and are used for serial ototoxicity monitoring in pediatric …

Objectives: Pediatric vestibular evaluations incorporate cervical and ocular vestibular
evoked myogenic potential (c-and oVEMP, respectively) testing; however, in children, c-and …

Purpose The main aim of this study was to compare the efficacy of intratympanic
administration of dexamethasone and resveratrol in preventing cisplatin ototoxicity by …

Objective: Assessments of the medial olivocochlear reflex (MOCR) may have clinical utility.
The MOCR is measured using contralateral inhibition of otoacoustic emissions but …

Purpose: The purpose of this study was to develop a time-efficient music exposure and
testing paradigm that safely creates temporary cochlear dysfunction that could be used in …

Objective Distortion-product otoacoustic emission (DPOAE) levels are repeatable over time
in normal-hearing individuals making DPOAE levels an ideal measurement for monitoring …